E. Bel (Amsterdam, The Netherlands), F. Chung (London, United Kingdom)
Effects of a 12-month course with omalizumab on nasal polyps and basement membrane in severe atopic asthma
C. Micheletto, S. Tognella, F. Trevisan, M. Visconti, R. W. Dal Negro (Bussolengo, Italy)
|   |
Comparative effectiveness of add-on omalizumab for the treatment of severe persistent asthma between current and former smokers vs. non-smokers
A. Michils, C. S. Lee, S. Gurdain, S. Vancayzeele, P. Lecomte, C. Hermans, K. MacDonald, I. Abraham (Brussels, Vilvoorde, Belgium; Earlysville, United States Of America)
| |
Neomacrolides in the treatment of patients with severe asthma and/or bronchiectasis: A retrospective observational study
M. Coeman, Y. van Durme, F. Bauters, I. Demedts, E. Deschepper, G. Joos, G. Brusselle (Belgium)
| |
Utility of inhaled corticosteroids (fluticasone/formoterol) by pressurized metered-dose inhaler for the early management of acute exacerbations of asthma
S. K. Agarwal, S. Sharma (Varanasi, India)
| |
Comparative safety-efficacy trial using three inhaler combinations in moderate persistent asthma
K. Saha, S. Sarkar (Kolkata, India)
| |
Oral glucocorticoid treatment of severe asthma – Current practice in the US
M. Lüttgen, A. Rummel, A. Batra, I. Mitar (Mannheim, Rueckersdorf/Nuremberg, Germany)
| |
Glucocorticoid receptor gene polymorphism in Chinese steroid-resistant asthma patients
F. Zhao, C. Wu, Y. Liu, A. Wang, L. Cai, X. Ti, H. Ouyang, J. Shi, Z. Li (Xi‘an, China)
| |
Effect of mometasone furoate/formoterol combination therapy on nocturnal awakenings in subjects with persistent asthma
D. Pearlman, R. Nathan, E. Meltzer, H. Nolte, S. Weinstein (Denver, Colorado Springs, San Diego, Kenilworth, Huntington Beach, United States Of America)
| |
Dose response to inhaled fluticasone/salmeterol measured with extended exhaled nitric oxide in refractory asthma
P. Williamson, S. Vaidyanathan, K. Clearie, B. Lipworth (Dundee, United Kingdom)
| |
Efficacy and safety of medium and high doses of mometasone furoate/formoterol combination treatment in subjects with severe asthma
S. Weinstein, K. Murphy, J. Corren, H. Nolte, M. White (Huntington Beach, Omaha, Los Angeles, Kenilworth, Wheaton, United States Of America)
| |
Effect of omalizumab on the risk of hospitalisation in patients with uncontrolled severe asthma in real-life. The PAX-LASER cohort
M. Zureik, M. Molimard, M. Aubier, J. Levy, M. Humbert, L. Grimaldi-Bensouda, L. Abenhaim, Pharmacoepidemiology of Asthma and Xolair® (PAX) Study Group (Paris, Bordeaux, , Clamart, France)
| |
Long-term (5 year) safety of bronchial thermoplasty in patients with moderate to severe asthma: Asthma Intervention Research (AIR) Trial
N. Thomson, R. Niven, C. Prys-Picard, P. Corris, R. Olivenstein, H. C. Siersted, I. Pavord, G. Cox, D. McCormack, A. Rubin, M. Laviolette (Glasgow, Manchester, Newcastle upon Tyne, Leicester, United Kingdom; Galveston, United States Of America; Montreal, Hamilton, Ontario, Quebec, Canada; , Denmark; Santa Casa de Porto Alegre, Brazil)
| |
Pharmacogenetic markers of steroid dependent bronchial asthma (BA) control
M. Simakova, Z. Mironova, V. Trofimov, V. Belash, E. Iantchina, M. Dubina (St. Petersburg, Russian Federation)
| |
Phenotype specific responses to methotrexate (MTX) in refractory asthma
N. Martin, B. Hargadon, P. Haldar, R. Green, A. Wardlaw, I. Pavord (Leicester, United Kingdom)
| |
Omalizumab in patients with moderate-to-severe persistent asthma poorly controlled on high-dose inhaled corticosteroids and long-acting beta-agonists: Results of a phase IIIb randomized controlled trial
N. Hanania, J. Condemi, D. Hamilos, I. Reyes-Rivera, K. E. Rosen, D. Wong, W. Busse (Houston, Rochester, Boston, South San Francisco, Madison, United States Of America)
| |
Simvastatin in the treatment of eosinophilic asthma
D. Cowan, J. Cowan, R. Palmay, A. Williamson, D. R. Taylor (Dunedin, New Zealand)
| |
Efficacy and safety of combined mometasone furoate/formoterol 200/10μg in persistent asthmatics
R. Nathan, D. Pearlman, H. Nolte, A. Nayak (Colorado Springs, Denver, Kenilworth, Normal, United States Of America)
| |